Following comprehensive governance and structural reviews, in 2020, ACTA amended the Constitution in order to improve the operational efficiency of the organisation. This was an important step towards one of our key strategies to build a sustainable and well-run organisation.
Latest Resource
-
Approaches to prioritising research
for clinical trial networks: a scoping review -
HEAT Webinar Recording- Economic Evaluation Alongside Adaptive Trials
-
ACTA 2021-2022 Annual Report
-
Effective strategies to manage data integrity risks webinar
-
The Data Lifecycle: Ethical use of data webinar
-
Transparency in data analyses webinar
-
Economic evaluation alongside cluster trial – webinar recording
-
Development of the Consumer Involvement and Engagement Toolkit
-
Activities supporting the growth of Clinical Trial Networks in Australia
-
Strengthening the capacity, efficiency and effectiveness of Clinical Trials Networks: Activity Overview 2017–2021
-
ACTA 2020-2021 Annual Report
-
ACTA Whistleblower Policy
-
MEDIA RELEASE: ACTA appoints Prof Steve Webb as its new Chair and Ian Wilson as Additional Independent Director
-
Official Opening of the 2020 ACTA Summit: Minister’s Address
-
ACTA Year in Review: Financial Year 2019-2020
-
ACTA submission: Parliamentary Inquiry into approval processes for new drugs and novel medical technologies in Australia
-
Statistical Analysis Plan (SAP)
-
ACTA Board Charter
-
Media Release: Australian Clinical Trials Alliance commends the Health Minister’s vision to expedite clinical trials in Australia
-
ACTA Trial of the Year Award 2020 guidelines and nomination forms
-
ACTA Year in Review: Financial Year 2018-2019
-
ACTA Resources Brochure
-
ACTA activity work plan 2019 – 2020
-
Report on the activities and achievements of clinical trials networks in Australia 2004 – 2014
-
What a trialist should know about implementation to practice
-
Submission to MRFF Consultation
-
Submission to Medical Research Future Fund Priority Consultation
-
Medical Research Future Fund – clinical trial funding set to deliver significant benefits to Australian patients and the economy
-
ACTA Advisory Council minutes July 2017
-
Economic evaluation of investigator-initiated clinical trials conducted by networks
-
Economic evaluation of investigator-initiated clinical trials conducted by networks – Appendix: Individual trial-level results
-
Open letter to the Hon Greg Hunt MP following announcement of MRFF funding for ACTA and clinical trials
-
Opportunities for linking evidence development to reimbursement in Australia
-
Clinical Quality Registries: A national approach
-
How can clinical trials networks drive better translation of evidence into better quality care?
-
The Global Perspective: Measuring the impact of Australian-led trials & registries internationally